Artivila Biopharma is a leading clinical-stage biotechnology company dedicated to advancing innovative drug discovery through its proprietary AI platform. Founded in late 2018 by top pharmaceutical experts, our mission is to address the intrinsic demands of the biopharmaceutical industry via an advanced AIDD (Artificial Intelligence-Driven Drug Discovery) and CADD (Computer-Aided Drug Design) integrated drug discovery platform. With years of successful drug discovery expertise and a strong track record, we focus on three therapeutic areas- Autoimmune Diseases, Neurodegenerative Diseases, and Cancers-all of which represent substantial unmet medical needs for patients worldwide. Our robust innovative drug discovery capabilities ensure the depth, breadth, and high value of our pipeline, encompassing mostly First-in-class projects and some Best-in-class opportunities.

 Recently, our leading asset ARD-885 has completed a Phase 1 study with excellent PK/PD and safety profiles. Phase 2 trials are in preparation for RA and SLE patients.

We have built a highly skilled and experienced research team, led by top computational chemist Dr. Zhendong Zhu and medicinal chemist Dr. Deqiang Niu—both with over 20 years of industry expertise. Our team comprises seasoned scientists trained at world-class institutions, including the University of Cambridge (UK), Columbia University (USA), ETH Zurich (Switzerland), and Peking University (China), among others. The company has about sixty employees, including more than 20 PhD-holding scientists, half of whom possess overseas study and work experience. Supported by this exceptional scientific team, together with our advanced CADD and AIDD platform, Artivila is well-positioned for sustained success in drug discovery and development.

Since our inception, we have successfully completed three rounds of fundraising, garnering recognition from numerous leading biopharmaceutical investors and funds. Cumulative funding has reached 298 million CNY (42 million USD), laying a solid financial foundation for the company’s rapid and steady growth.

At Artivila, we are unwaveringly committed to improving the health of patients with unmet medical needs worldwide through our relentless pursuit of translating scientific breakthroughs from the bench to bedside.